Lemieux nouveau CFO at Nuvo
This article was originally published in Scrip
Canadian specialty pharmaceutical company Nuvo Research, which is building a portfolio for the topical treatment of pain, has appointed Stephen Lemieux vice-president and chief financial officer following the resignation of James Moulds. Mr Lemieux was previously vice-president of finance and corporate controller at Nuvo. Mr Moulds, who joined the company in 2006, has left to pursue other opportunities.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.